JP4361493B2 - 腹膜透析用薬剤の製造のための医学的溶液を調製する方法 - Google Patents
腹膜透析用薬剤の製造のための医学的溶液を調製する方法 Download PDFInfo
- Publication number
- JP4361493B2 JP4361493B2 JP2004558967A JP2004558967A JP4361493B2 JP 4361493 B2 JP4361493 B2 JP 4361493B2 JP 2004558967 A JP2004558967 A JP 2004558967A JP 2004558967 A JP2004558967 A JP 2004558967A JP 4361493 B2 JP4361493 B2 JP 4361493B2
- Authority
- JP
- Japan
- Prior art keywords
- solution
- nag
- compartment
- acetylglucosamine
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 238000000502 dialysis Methods 0.000 title claims abstract description 28
- 239000008155 medical solution Substances 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 8
- 229940079593 drug Drugs 0.000 title description 3
- 239000000243 solution Substances 0.000 claims abstract description 102
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 43
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 78
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 78
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 78
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 78
- 230000001954 sterilising effect Effects 0.000 claims description 43
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 28
- 239000008103 glucose Substances 0.000 claims description 28
- 239000000385 dialysis solution Substances 0.000 claims description 14
- 239000007857 degradation product Substances 0.000 claims description 11
- 231100000433 cytotoxic Toxicity 0.000 claims description 8
- 230000001472 cytotoxic effect Effects 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 238000007865 diluting Methods 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 238000010979 pH adjustment Methods 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 150000002337 glycosamines Chemical class 0.000 abstract description 36
- 235000000346 sugar Nutrition 0.000 abstract 1
- 150000008163 sugars Chemical class 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 20
- 239000011734 sodium Substances 0.000 description 20
- 229910052708 sodium Inorganic materials 0.000 description 20
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 13
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 13
- 239000011575 calcium Substances 0.000 description 13
- 229910052791 calcium Inorganic materials 0.000 description 13
- 239000011777 magnesium Substances 0.000 description 13
- 229910052749 magnesium Inorganic materials 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 12
- 229940001447 lactate Drugs 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 238000006731 degradation reaction Methods 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003792 electrolyte Substances 0.000 description 5
- 210000003200 peritoneal cavity Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229940099552 hyaluronan Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- -1 organic acid salts Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001065350 Lundia Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000017095 negative regulation of cell growth Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000003330 peritoneal dialysis fluid Substances 0.000 description 2
- 210000003245 peritoneal mesothelial cell Anatomy 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- WNKYVCKDIDTELO-NJXYFUOMSA-N (2r)-6-hydroxy-2-(hydroxymethyl)-2h-pyran-5-one Chemical compound OC[C@@H]1OC(O)C(=O)C=C1 WNKYVCKDIDTELO-NJXYFUOMSA-N 0.000 description 1
- LCTORNIWLGOBPB-PHYPRBDBSA-N (2s,3r,4s,5r,6r)-2-amino-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound N[C@@]1(O)O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LCTORNIWLGOBPB-PHYPRBDBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 208000012896 Peritoneal disease Diseases 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- External Artificial Organs (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
腹膜透析のために通常使用される透析液は、浸透圧物質、例えばグルコースおよびその類縁体、電解質、例えばナトリム、カリウム、カルシウム、マグネシウム、および有機酸塩、例えば乳酸ナトリウム、重炭酸ナトリウム、またはピルビン酸ナトリウムを含む水溶液である。これらの腹膜透析液体の成分は、電解質または酸−塩基平衡のレベルを制御し、老廃物を除去し、および限外ろ過を効果的に行うように選択される。
a)1以上のアセチル化またはジアセチル化されたアミノ糖を含む溶液を、容器の少なくとも1つの区画内に、前記少なくとも1つの区画内の溶液に基づいて20〜40重量%の濃度で提供する工程と、
b)前記少なくとも1つの区画およびその内容物を最終的に殺菌する工程と
を含む方法によって達成される。
を示し、最終的殺菌工程中の細胞傷害性物質の形成が実質的に妨げられる。
例1
区画A 容積 100ml
ナトリウム 0-140ml
NAG 300g/l
区画B 容積 180ml
ナトリウム 0-140 mM
NAG 300g/l
区画C 容積 1900ml
ナトリウム 0-140 mM
乳酸塩 40 mM
マグネシウム 0.25-0.75 mM
カルシウム 0.9-2.0 mM
容積 2000ml
ナトリウム 0-140 mM
NAG 15g/l
乳酸塩 38 mM
マグネシウム 0.24-0.71 mM
カルシウム 0.85-1.9 mM
容積 2080ml
ナトリウム 0-140 mM
NAG 26g/l
乳酸塩 36.5 mM
マグネシウム 0.22-0.68 mM
カルシウム 0.82-1.8 mM
容積 2180ml
ナトリウム 0-140 mM
NAG 38.5g/l
乳酸塩 34.9 mM
マグネシウム 0.21-0.65 mM
カルシウム 0.78-1.7 mM
区画A 容積 100ml
ナトリウム 0-140mM
NAG 300g/l
区画B 容積 180ml
ナトリウム 0-140 mM
グルコース 500g/l
区画C 容積 1900ml
ナトリウム 0-140 mM
乳酸塩 40 mM
マグネシウム 0.25-0.75 mM
カルシウム 0.9-2.0 mM
容積 2000ml
ナトリウム 0-140 mM
NAG 15g/l
グルコース 0 g/l
乳酸塩 38 mM
マグネシウム 0.24-0.71 mM
カルシウム 0.85-1.9 mM
容積 2100 ml
ナトリウム 0-140 mM
NAG 14.3 g/l
グルコース 23.8 g/l
乳酸塩 36 mM
マグネシウム 0.23-0.68 mM
カルシウム 0.81-1.8 mM
区画A 容積 60 ml
ナトリウム 0-140 ml
NAG 200 g/l
グルコース 330 g/l
区画B 容積 100 ml
ナトリウム 0-140 mM
NAG 200 g/l
グルコース 330 g/l
区画C 容積 1900 ml
ナトリウム 0-140 mM
乳酸塩 40 mM
マグネシウム 0.25-0.75 mM
カルシウム 0.9-2.0 mM
容積 1960 ml
ナトリウム 0-140 mM
NAG 6.2 g/l
グルコース 10.1 g/l
乳酸塩 38.8 mM
マグネシウム 0.24-0.73 mM
カルシウム 0.87-1.9 mM
容積 2000 ml
ナトリウム 0-140 mM
NAG 10.0 g/l
グルコース 16.5 g/l
乳酸塩 38.0 mM
マグネシウム 0.24-0.71 mM
カルシウム 0.86-1.9 mM
容積 2060 ml
ナトリウム 0-140 mM
NAG 15.5 g/l
グルコース 25.6 g/l
乳酸塩 37 mM
マグネシウム 0.23-0.69 mM
カルシウム 0.83-1.8 mM
本発明の好ましい実施形態を参照しながら本発明について上述してきた。当業者は、さらなる組合せが可能であることを認識するであろう。当業者にとって明らかな改変は、本発明の範囲内に組み込まれ、添付された特許請求の範囲によってのみ制限される。
Claims (24)
- 医学的溶液を調製する方法であって、
a) N-アセチルグルコサミン(NAG)を含む溶液を、容器の少なくとも1つの区画内に、前記少なくとも1つの区画内の溶液に基づいて15〜40重量%の濃度で提供する工程と、
b)前記少なくとも1つの区画およびその内容物を最終的に殺菌する工程と
を含む方法。 - 前記容器の前記少なくとも1つの区画内にある前記N-アセチルグルコサミン(NAG)が、前記少なくとも1つの区画内の溶液に基づいて20〜40重量%の濃度で与えられる請求項1に記載の方法。
- 前記容器の前記少なくとも1つの区画内にある前記N-アセチルグルコサミン(NAG)が、前記少なくとも1つの区画内の溶液に基づいて少なくとも30重量%の濃度で与えられる請求項1に記載の方法。
- 前記容器の前記少なくとも1つの区画内にある前記N-アセチルグルコサミン(NAG)を含む溶液が、2.0〜5.0のpHで与えられる請求項1ないし3のいずれか1項に記載の方法。
- 前記pHが2.5〜3.5である請求項4に記載の方法。
- 前記pHが3.0である請求項4に記載の方法。
- 前記最終的殺菌が、少なくとも100℃の温度での熱殺菌、および/または放射線殺菌である請求項1ないし6のいずれか1項に記載の方法。
- 請求項7に記載の方法であって、前記熱殺菌が、121℃の温度での熱殺菌である方法。
- 前記容器の各区画を、最終的殺菌中に他の区画から区切り、N-アセチルグルコサミン(NAG)を含む最終的に殺菌された溶液を、前記容器の少なくとも1つの他の最終的に殺菌された区画中で、最終的に殺菌されたpH調整および希釈溶液と混合させ、それによって医学的溶液を最終的に調製する請求項1ないし8のいずれか1項に記載の方法。
- 最終的に調製された医学的溶液中のpHが6.0〜8.0である請求項9に記載の方法。
- 最終的に調製された医学的溶液中のpHが7.4である請求項9に記載の方法。
- 最終的に調製された溶液中のN-アセチルグルコサミン(NAG)の濃度が、0.2〜15.0重量%である請求項9ないし11の何れか一項に記載の方法。
- 請求項12に記載の方法であって、前記N-アセチルグルコサミン(NAG)の濃度が、0.5〜6.0重量%である方法。
- 炭水化物、タンパク質、ペプチド、および酸化防止剤の形態の生理学的適合性の成分が、1以上の前記区画中に存在する請求項1ないし13のいずれか1項に記載の方法。
- 前記炭水化物がグルコースである、請求項14に記載の方法。
- 調製された医学的溶液が、腹膜透析溶液である請求項1ないし15のいずれか1項に記載の方法。
- N-アセチルグルコサミン(NAG)を、15〜40重量%の量で含む溶液であって、最終的に最後のパッケージにおいて殺菌され、低度の細胞傷害性分解生成物を含む溶液。
- 請求項17に記載の溶液であって、前記N-アセチルグルコサミン(NAG)を、20〜40重量%の量で含む溶液。
- 請求項17に記載の溶液であって、前記N-アセチルグルコサミン(NAG)を、少なくとも30重量%の量で含む溶液。
- 前記溶液のpHが、2.0〜5.0である請求項17ないし19の何れか一項に記載の溶液。
- 請求項20に記載の溶液であって、前記pHが2.5〜3.5である溶液。
- 請求項20に記載の溶液であって、前記pHが3.0である溶液。
- 請求項17ないし22のいずれか1項に記載の溶液を入れる少なくとも1つの区画を備える容器。
- 腹膜透析用薬剤の製造のための請求項17ないし22のいずれか1項に記載の溶液の使用であって、前記溶液が最終的に殺菌されたpH調整および希釈溶液と混合される使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43258102P | 2002-12-10 | 2002-12-10 | |
SE0203672A SE524531C2 (sv) | 2002-12-10 | 2002-12-10 | Metod för att framställa en medicinsk lösning för peritonealdialys där en lösning innehållandes ett eller flera acetylerade eller deacetylerade aminosocker värme- eller strålningssteriliseras med bestämda pH-värden och med bestämda viktsprocent för att undvika att cytotoxiska produkter bildas |
PCT/SE2003/001921 WO2004052269A1 (en) | 2002-12-10 | 2003-12-10 | A method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006509556A JP2006509556A (ja) | 2006-03-23 |
JP4361493B2 true JP4361493B2 (ja) | 2009-11-11 |
Family
ID=32510745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004558967A Expired - Lifetime JP4361493B2 (ja) | 2002-12-10 | 2003-12-10 | 腹膜透析用薬剤の製造のための医学的溶液を調製する方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20060046975A1 (ja) |
EP (1) | EP1569595B1 (ja) |
JP (1) | JP4361493B2 (ja) |
KR (1) | KR101142864B1 (ja) |
AT (1) | ATE395897T1 (ja) |
AU (1) | AU2003283940B2 (ja) |
CA (1) | CA2508596A1 (ja) |
DE (1) | DE60321213D1 (ja) |
ES (1) | ES2306901T3 (ja) |
WO (1) | WO2004052269A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1569596B1 (en) | 2002-12-10 | 2008-08-06 | Gambro Lundia AB | A method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis |
US7235589B2 (en) * | 2004-09-21 | 2007-06-26 | Bio Numerik Pharmaceuticals, Inc. | Method of treating patients undergoing kidney dialysis |
TWI388318B (zh) | 2005-03-10 | 2013-03-11 | Sigma Tau Ind Farmaceuti | 具有改良之生物相容性的含有肉毒鹼之腹膜透析溶液 |
US20070155672A1 (en) * | 2006-01-05 | 2007-07-05 | Markus Voges | Sterilized peritoneal dialysis solutions containing heparin |
WO2007104576A1 (de) * | 2006-03-16 | 2007-09-20 | Mosetter, Kurt | Arzneimittel enthaltend n-acetyl-mannosamin oder derivate hiervon und seine verwendung |
KR102022338B1 (ko) * | 2018-08-06 | 2019-09-18 | 이건무 | 당과 아미노산을 함유하는 안정한 수액제 조성물 |
EP3912656A1 (en) | 2020-05-19 | 2021-11-24 | CoreQuest Sagl | Peritoneal dialysis solution |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1792346C3 (de) * | 1968-08-22 | 1980-10-23 | Rotta Research Laboratorium S.P.A., San Fruttuoso Di Monza, Mailand (Italien) | Pharmazeutisches Präparat für die Behandlung von degenerativen Gelenkerkrankungen |
SE9103395D0 (sv) * | 1991-11-18 | 1991-11-18 | Gambro Ab | System med anvaendning av ensteril medicinsk loesning innehaallande glukos eller glukosliknande aemnen samt en loesning avsedd foer detta system |
US5716597A (en) * | 1993-06-04 | 1998-02-10 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
CA2155910C (en) * | 1995-08-11 | 1999-12-14 | George Wu | Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis |
SE512349C2 (sv) * | 1997-11-28 | 2000-03-06 | Gambro Lundia Ab | Flerkammarbehållare för medicinsk lösning, förfarnde för beredning av medicinsk lösning för peritonealdialys samt användning av sådan behållare vid beredning av medicinsk lösning |
EP1569596B1 (en) * | 2002-12-10 | 2008-08-06 | Gambro Lundia AB | A method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis |
-
2003
- 2003-12-10 WO PCT/SE2003/001921 patent/WO2004052269A1/en active Application Filing
- 2003-12-10 US US10/538,791 patent/US20060046975A1/en not_active Abandoned
- 2003-12-10 KR KR1020057010471A patent/KR101142864B1/ko active IP Right Grant
- 2003-12-10 JP JP2004558967A patent/JP4361493B2/ja not_active Expired - Lifetime
- 2003-12-10 CA CA002508596A patent/CA2508596A1/en not_active Abandoned
- 2003-12-10 DE DE60321213T patent/DE60321213D1/de not_active Expired - Lifetime
- 2003-12-10 EP EP03776162A patent/EP1569595B1/en not_active Expired - Lifetime
- 2003-12-10 AU AU2003283940A patent/AU2003283940B2/en not_active Expired
- 2003-12-10 ES ES03776162T patent/ES2306901T3/es not_active Expired - Lifetime
- 2003-12-10 AT AT03776162T patent/ATE395897T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1569595A1 (en) | 2005-09-07 |
CA2508596A1 (en) | 2004-06-24 |
JP2006509556A (ja) | 2006-03-23 |
KR101142864B1 (ko) | 2012-05-21 |
DE60321213D1 (de) | 2008-07-03 |
AU2003283940A1 (en) | 2004-06-30 |
US20060046975A1 (en) | 2006-03-02 |
KR20050084225A (ko) | 2005-08-26 |
ATE395897T1 (de) | 2008-06-15 |
AU2003283940B2 (en) | 2008-09-11 |
WO2004052269A1 (en) | 2004-06-24 |
EP1569595B1 (en) | 2008-05-21 |
ES2306901T3 (es) | 2008-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1585531B1 (en) | Biocompatible dialysis fluids containing icodextrins | |
US9918999B2 (en) | Method for preparing a medical solution for the manufacture of a medicament for peritoneal dialysis | |
EP0456806B1 (en) | Histidine buffered peritoneal dialysis solution | |
JP5475671B2 (ja) | ピロホスフェートを含む滅菌透析溶液 | |
JP4361493B2 (ja) | 腹膜透析用薬剤の製造のための医学的溶液を調製する方法 | |
JP3871442B2 (ja) | 腹膜透析液 | |
CN100389740C (zh) | 用于生产腹膜透析药物的医用溶液的制备方法 | |
CN100389741C (zh) | 用于生产腹膜透析药物的医用溶液的制备方法 | |
JP4802492B2 (ja) | ヘパリン含有プレフィルドシリンジ製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060516 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090525 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090714 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090812 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4361493 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120821 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120821 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130821 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |